Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Vaxcyte.

    Client Virtual Booth

    VAXCYTE

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Vaxcyte
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    825 Industrial Road, Suite 300 San Carlos, CA 94070
    Telephone
    Telephone
    (650) 837-0111
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://vaxcyte.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/vaxcyte/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

    Details:

    Vaxcyte's VAX-24 is a 24-valent Pneumococcal conjugate vaccine, presently undergoing Phase II clinical trials specifically for infants to treat Invasive Pneumococcal disease.


    Lead Product(s): VAX-24

    Therapeutic Area: Infections and Infectious Diseases Product Name: VAX-24

    Highest Development Status: Phase IIProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 04, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    Details:

    The net proceeds will be used to fund clinical development of the VAX-24, a Phase 3-ready 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine and VAX-31, next-generation 31-valent PCV, adult and pediatric programs.


    Lead Product(s): VAX-24

    Therapeutic Area: Infections and Infectious Diseases Product Name: VAX-24

    Highest Development Status: Phase IIProduct Type: Vaccine

    Partner/Sponsor/Collaborator: BofA Securities

    Deal Size: $862.5 million Upfront Cash: Undisclosed

    Deal Type: Public Offering February 02, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Vaxcyte Announces Pricing of $750 Million Public Offering

    Details:

    The net proceeds will be used to fund clinical development of the VAX-24, a Phase 3-ready 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine and VAX-31, next-generation 31-valent PCV, adult and pediatric programs.


    Lead Product(s): VAX-24

    Therapeutic Area: Infections and Infectious Diseases Product Name: VAX-24

    Highest Development Status: Phase IIProduct Type: Vaccine

    Partner/Sponsor/Collaborator: BofA Securities

    Deal Size: $750.0 million Upfront Cash: Undisclosed

    Deal Type: Public Offering January 30, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

    Details:

    The net proceeds will be used to fund clinical development of the VAX-24, a Phase 3-ready 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine and VAX-31, next-generation 31-valent PCV, adult and pediatric programs.


    Lead Product(s): VAX-24

    Therapeutic Area: Infections and Infectious Diseases Product Name: VAX-24

    Highest Development Status: Phase IIProduct Type: Vaccine

    Partner/Sponsor/Collaborator: BofA Securities

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Public Offering January 30, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older

    Details:

    VAX-31 is a 31-valent pneumococcal conjugate vaccine (PCV) candidate which is under phase 1/2 clinical trials to prevent invasive pneumococcal disease (IPD), in healthy adults aged 50 and older.


    Lead Product(s): 31-valent Pneumococcal Conjugate Vaccine

    Therapeutic Area: Infections and Infectious Diseases Product Name: VAX-31

    Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 29, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise

    Details:

    VAX-31 (31 valent pneumococcal conjugate vaccine) is an investigational PCV candidate, designed to prevent invasive pneumococcal disease. It is especially serious in infants, young children, older adults, and those with immune deficiencies or certain chronic health conditions.


    Lead Product(s): 31-valent Pneumococcal Conjugate Vaccine

    Therapeutic Area: Infections and Infectious Diseases Product Name: VAX-31

    Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 04, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cel...

    Details:

    Under the agreement, Vaxcyte obtains exclusive rights to independently develop and manufacture cell-free extract, a key component of the company’s 24-valent pneumococcal conjugate vaccine (PCV) franchise which includes VAX-24 and VAX-31.


    Lead Product(s): 24-valent Pneumococcal Conjugate Vaccine

    Therapeutic Area: Infections and Infectious Diseases Product Name: VAX-24

    Highest Development Status: Phase IIProduct Type: Vaccine

    Recipient: Sutro Biopharma

    Deal Size: $135.0 million Upfront Cash: $135.0 million

    Deal Type: Agreement November 27, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

    Details:

    VAX-31, an investigational 31-valent PCV candidate, is designed to prevent IPD, which is especially serious in infants, young children, older adults, and those with immune deficiencies or certain chronic health conditions.


    Lead Product(s): 31-valent Pneumococcal Conjugate Vaccine

    Therapeutic Area: Infections and Infectious Diseases Product Name: VAX-31

    Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 09, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

    Details:

    VAX-31, an investigational 31-valent PCV candidate, is designed to prevent IPD, which is especially serious in infants, young children, older adults, and those with immune deficiencies or certain chronic health conditions.


    Lead Product(s): 31-valent Pneumococcal Conjugate Vaccine

    Therapeutic Area: Infections and Infectious Diseases Product Name: VAX-31

    Highest Development Status: IND EnablingProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 19, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)

    Details:

    Under the expanded collaboration, Vaxcyte will utilise existing Lonza infrastructure to advance clinical development and commercialization of Vaxcyte’s PCV candidates, VAX-24, a 24-valent pneumococcal conjugate vaccine and VAX-31, in both the adult and pediatric populations.


    Lead Product(s): 24-valent Pneumococcal Conjugate Vaccine

    Therapeutic Area: Infections and Infectious Diseases Product Name: VAX-24

    Highest Development Status: Phase IIProduct Type: Vaccine

    Recipient: Lonza Group

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Expanded Collaboration October 16, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search